IL158222A0 - Anti-inflammatory 17. beta-carbothioate ester derivatives of androstane with a cyclic ester group in position 17. alpha - Google Patents

Anti-inflammatory 17. beta-carbothioate ester derivatives of androstane with a cyclic ester group in position 17. alpha

Info

Publication number
IL158222A0
IL158222A0 IL15822202A IL15822202A IL158222A0 IL 158222 A0 IL158222 A0 IL 158222A0 IL 15822202 A IL15822202 A IL 15822202A IL 15822202 A IL15822202 A IL 15822202A IL 158222 A0 IL158222 A0 IL 158222A0
Authority
IL
Israel
Prior art keywords
androstane
inflammatory
beta
alpha
carbothioate
Prior art date
Application number
IL15822202A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0110578A external-priority patent/GB0110578D0/en
Priority claimed from GB0127988A external-priority patent/GB0127988D0/en
Priority claimed from GB0202442A external-priority patent/GB0202442D0/en
Priority claimed from GB0202637A external-priority patent/GB0202637D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL158222A0 publication Critical patent/IL158222A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15822202A 2001-04-30 2002-04-30 Anti-inflammatory 17. beta-carbothioate ester derivatives of androstane with a cyclic ester group in position 17. alpha IL158222A0 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0110578A GB0110578D0 (en) 2001-04-30 2001-04-30 Novel compounds
GB0127988A GB0127988D0 (en) 2001-11-22 2001-11-22 Novel compounds
GB0202442A GB0202442D0 (en) 2002-02-02 2002-02-02 Novel compounds
GB0202637A GB0202637D0 (en) 2002-02-05 2002-02-05 Novel compounds
PCT/GB2002/001971 WO2002088167A1 (en) 2001-04-30 2002-04-30 Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha

Publications (1)

Publication Number Publication Date
IL158222A0 true IL158222A0 (en) 2004-05-12

Family

ID=27447944

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15822202A IL158222A0 (en) 2001-04-30 2002-04-30 Anti-inflammatory 17. beta-carbothioate ester derivatives of androstane with a cyclic ester group in position 17. alpha

Country Status (25)

Country Link
US (2) US7291608B2 (ko)
EP (2) EP1383786B1 (ko)
JP (1) JP4446661B2 (ko)
KR (1) KR100831534B1 (ko)
CN (1) CN1302007C (ko)
AR (1) AR033290A1 (ko)
AT (1) ATE411334T1 (ko)
AU (2) AU2002253342B2 (ko)
BR (1) BR0209271A (ko)
CA (1) CA2445839A1 (ko)
CZ (1) CZ20032958A3 (ko)
DE (1) DE60229372D1 (ko)
DK (1) DK1383786T3 (ko)
ES (1) ES2314052T3 (ko)
HK (1) HK1062020A1 (ko)
HU (1) HUP0400070A2 (ko)
IL (1) IL158222A0 (ko)
MX (1) MXPA03009940A (ko)
MY (1) MY137522A (ko)
NO (1) NO326015B1 (ko)
NZ (1) NZ528888A (ko)
PL (1) PL366937A1 (ko)
PT (1) PT1383786E (ko)
SI (1) SI1383786T1 (ko)
WO (1) WO2002088167A1 (ko)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
EP1383786B1 (en) * 2001-04-30 2008-10-15 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
WO2003048181A1 (en) * 2001-12-01 2003-06-12 Glaxo Group Limited 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
WO2003072592A1 (en) * 2002-01-15 2003-09-04 Glaxo Group Limited 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
UA83017C2 (uk) * 2002-11-27 2008-06-10 Нікомед Гмбх Комбінація рофлуміласту та r,r-формотеролу для лікування захворювань дихальних шляхів
UA83018C2 (uk) * 2002-11-27 2008-06-10 Нікомед Гмбх Комбінація рофлуміласту і формотеролу для лікування захворювань дихальних шляхів
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0316290D0 (en) * 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
AU2006270165B2 (en) 2005-07-14 2010-03-11 Neothetics, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
CA2618089A1 (en) 2005-08-08 2007-02-15 Argenta Discovery Ltd. Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
TW200744612A (en) * 2005-08-26 2007-12-16 Astrazeneca Ab New combination
EP2532679B1 (en) 2005-10-21 2017-04-12 Novartis AG Human antibodies against il13 and therapeutic uses
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
BRPI0710240A2 (pt) 2006-04-20 2011-08-09 Glaxo Group Ltd composto, uso de um composto, método para o tratamento de um paciente humano ou animal com uma condição ou doença, composição farmacêutica, combinação, e, processo para a preparação de um composto
US8258141B2 (en) 2006-04-21 2012-09-04 Novartis Ag Organic compounds
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
AU2007275931B2 (en) 2006-07-19 2011-06-16 Astrazeneca Ab Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity
ATE502943T1 (de) 2006-09-29 2011-04-15 Novartis Ag Pyrazolopyrimidine als pi3k-lipidkinasehemmer
ES2398480T3 (es) * 2006-10-17 2013-03-19 Lithera, Inc. Procedimientos, composiciones, y formulaciones para el tratamiento de la enfermedad ocular tiroidea
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
KR20090094460A (ko) 2006-12-19 2009-09-07 아스트라제네카 아베 무스카린 수용체 길항제로서 퀴누클리디놀 유도체
DE602007011670D1 (de) 2007-01-10 2011-02-10 Irm Llc Verbindungen und zusammensetzungen als kanal-aktivierende proteasehemmer
EP2117541A1 (en) 2007-02-09 2009-11-18 Irm Llc Compounds and compositions as channel activating protease inhibitors
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
EA200901489A1 (ru) 2007-05-07 2010-04-30 Новартис Аг Органические соединения
US8048980B2 (en) * 2007-09-17 2011-11-01 Bezwada Biomedical, Llc Hydrolysable linkers and cross-linkers for absorbable polymers
NZ584160A (en) 2007-10-04 2011-05-27 Astrazeneca Ab Steroidal [3,2-c] pyrazole compounds, with glucocorticoid activity
AU2008334629B2 (en) 2007-12-10 2012-04-12 Novartis Ag Organic compounds
WO2009087224A1 (en) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
AU2008356409B2 (en) 2008-05-13 2012-01-19 Astrazeneca Ab Quinuclidine derivatives as muscarinic M3 receptor antagonists
MX2010012814A (es) 2008-05-23 2010-12-20 Amira Pharmaceuticals Inc Inhibidor de proteina activadora de 5-lipoxigenasa.
AU2009252938B2 (en) 2008-05-27 2012-04-26 Astrazeneca Ab Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states
JP5502858B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤として有用な４−カルボキサミドインダゾール誘導体
EP2300010B1 (en) 2008-06-10 2015-03-04 Novartis AG Pyrazine derivatives as epithelial sodium channel blockers
WO2010067102A1 (en) 2008-12-09 2010-06-17 Astrazeneca Ab Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
NZ594157A (en) 2008-12-30 2013-07-26 Pulmagen Therapeutics Inflammation Ltd Sulfonamide compounds for the treatment of respiratory disorders
TW201031406A (en) 2009-01-29 2010-09-01 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
JP5656880B2 (ja) 2009-03-09 2015-01-21 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
JP2012520845A (ja) 2009-03-17 2012-09-10 グラクソ グループ リミテッド Ｉｔｋ阻害剤として使用されるピリミジン誘導体
WO2010107958A1 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20120016011A1 (en) 2009-03-19 2012-01-19 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010107955A2 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING
WO2010107957A2 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111464A1 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2411019A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
KR20110138223A (ko) 2009-03-27 2011-12-26 머크 샤프 앤드 돔 코포레이션 짧은 간섭 핵산 (ｓｉＮＡ)을 사용한 세포간 부착 분자 1 (ＩＣＡＭ-1) 유전자 발현의 ＲＮＡ 간섭 매개 억제
WO2010111468A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
WO2010111490A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
UY32520A (es) 2009-04-03 2010-10-29 Astrazeneca Ab Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
UY32523A (es) * 2009-04-03 2010-10-29 Astrazeneca Ab Compuestos que tienen actividad agonista del receptor de glucocorticosteroides
UY32521A (es) * 2009-04-03 2010-10-29 Astrazeneca Ab Combinación para emplear en el tratamiento de enfermedades respiratorias
UY32525A (es) * 2009-04-03 2010-10-29 Astrazeneca Ab Compuestos que tienen actividad agonista del receptor de glucocorticosteroides
WO2010122089A1 (en) 2009-04-24 2010-10-28 Glaxo Group Limited N-pyrazolyl carboxamides as crac channel inhibitors
WO2010122088A1 (en) 2009-04-24 2010-10-28 Glaxo Group Limited Pyrazole and triazole carboxamides as crac channel inhibitors
MA33304B1 (fr) 2009-04-30 2012-05-02 Glaxo Group Ltd Indazoles substitués par oxazole comme inhibiteurs de pi3-kinase
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
MX2012001838A (es) 2009-08-12 2012-02-29 Novartis Ag Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
MY162604A (en) 2009-08-17 2017-06-30 Intellikine Llc Heterocyclic compounds and uses thereof
IN2012DN01453A (ko) 2009-08-20 2015-06-05 Novartis Ag
CA2777245A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
US20120245171A1 (en) 2009-12-03 2012-09-27 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of pi3 kinases
US20120238559A1 (en) 2009-12-03 2012-09-20 Glaxo Group Limited Novel compounds
JP2013512880A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３−キナーゼ阻害剤としてのインダゾール誘導体
GB2487868B (en) * 2010-01-15 2014-12-10 Neothetics Inc Lyophilized cake formulations
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
CN102250185B (zh) * 2010-05-19 2015-06-10 天津金耀集团有限公司 一种21位为nmda酯的糖皮质激素
EP2613781B1 (en) 2010-09-08 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Indazole derivatives for use in the treatment of influenza virus infection
JP5965402B2 (ja) 2010-09-08 2016-08-03 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｎ−［５−［４−（５−｛［（２ｒ，６ｓ）−２，６−ジメチル−４−モルホリニル］メチル｝−１，３−オキサゾール−２−イル）−１ｈ−インダゾール−６−イル］−２−（メチルオキシ）−３−ピリジニル］メタンスルホンアミドの多形体および塩
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
US9149462B2 (en) 2010-10-21 2015-10-06 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
EP2630126B1 (en) 2010-10-21 2015-01-07 Glaxo Group Limited Pyrazole compounds acting against allergic, immune and inflammatory conditions
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
TW201231042A (en) 2010-11-24 2012-08-01 Lithera Inc Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
WO2012116217A1 (en) 2011-02-25 2012-08-30 Irm Llc Compounds and compositions as trk inhibitors
JP2014507458A (ja) 2011-03-11 2014-03-27 グラクソ グループ リミテッド Ｓｙｋインヒビターとしてのピリド［３，４−Ｂ］ピラジン誘導体
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
CN102850426B (zh) * 2011-07-01 2015-12-02 天津金耀集团有限公司 一种21位为n-乙酰半胱氨酸酯的糖皮质激素
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
EP2755976B1 (en) 2011-09-15 2018-07-18 Novartis AG 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038390A1 (en) 2011-09-16 2013-03-21 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
EP2755967B1 (en) 2011-09-16 2015-10-21 Novartis AG Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
EP2793893A4 (en) 2011-11-23 2015-07-08 Intellikine Llc IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
CN104245701A (zh) 2012-04-03 2014-12-24 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
EP3007697B1 (en) 2013-06-14 2020-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Rac1 inhibitors for inducing bronchodilation
CN105658218A (zh) 2013-10-17 2016-06-08 葛兰素史克知识产权开发有限公司 用于治疗呼吸疾病的pi3k抑制剂
CA2925064A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
ES2667424T3 (es) 2014-04-24 2018-05-10 Novartis Ag Derivados de pirazina como inhibidores de fosfatidil-inositol-3-quinasa
BR112016024533A8 (pt) 2014-04-24 2021-03-30 Novartis Ag derivados de amino pirazina como inibidores de fosfatidilinositol 3-cinase ou sal, seu uso, e composição e combinação farmacêuticas
US10112926B2 (en) 2014-04-24 2018-10-30 Novartis Ag Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
PE20170185A1 (es) 2014-05-12 2017-04-01 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones farmaceuticas para tratar enfermedades infecciosas
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
AU2015294889B2 (en) 2014-07-31 2018-03-15 Novartis Ag Combination therapy
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
EP3497100A1 (en) 2016-08-08 2019-06-19 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
WO2020250116A1 (en) 2019-06-10 2020-12-17 Novartis Ag Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
US20220306617A1 (en) 2019-08-28 2022-09-29 Novartis Ag Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
JP2023519585A (ja) 2020-03-26 2023-05-11 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド ウイルス感染を予防または治療するカテプシン阻害剤

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR580494A (fr) 1923-07-10 1924-11-07 Const Metalliques Schiltigheim Procédé d'établissement des buses d'aération ou autres tuyaux
US2837464A (en) * 1955-01-11 1958-06-03 Schering Corp Process for production of dienes by corynebacteria
DE1059906B (de) 1954-10-05 1959-06-25 Scherico Ltd Verfahren zur Herstellung von 1, 4-Pregnadienen
US3067197A (en) 1961-04-26 1962-12-04 Pfizer & Co C 11-oxygenated 6alpha-fluoro-16-methylene-delta-pregnenes and derivatives
GB1047518A (en) * 1963-06-11 1966-11-02 Glaxo Lab Ltd 17ª‡-monoesters of 11,17,21-trihydroxy steroid compounds
GB1158492A (en) 1966-02-09 1969-07-16 Boots Pure Drug Co Ltd Improvements in Acylated Steroids
US3639434A (en) * 1967-02-02 1972-02-01 Boots Pure Drug Co Ltd 17-acyloxysteroids and their manufacture
GB1227992A (ko) * 1968-01-23 1971-04-15 Koninklijke Gist Spiritus
IT1034011B (it) 1969-06-26 1979-09-10 Vister Vismara Terapeutici S P Processo per la prapratzione di 17 monoesteri di 17 a 21 diossisteroidi per idrolisi die corpispondenti 17 21 ortoesteri ciclici a ph control lato
GB1384372A (en) 1971-01-20 1975-02-19 Glaxo Lab Ltd Dereivatives of 17alpha-hydroxyandrost-4-ene-17beta-carboxylic acids
US3828080A (en) 1972-01-20 1974-08-06 Glaxo Lab Ltd Androstane-17beta-carboxylic acids and processes for the preparation thereof
US3989686A (en) 1972-06-15 1976-11-02 Glaxo Laboratories Limited Anaesthetic steroids of the androstane series and process for preparing same
GB1438940A (en) 1972-07-19 1976-06-09 Glaxo Lab Ltd 17beta-haloalkoxycarbonyl-17alpha-oxysteroids
GB1440063A (en) * 1972-08-11 1976-06-23 Glaxo Lab Ltd 17alpha-esters of 17alpha,21-dihydroxy-20-oxo-steroids
DE2336693A1 (de) 1973-07-19 1975-02-06 Nassheuer Ind Ofenbau Jean Strahlheizrohr
GB1517278A (en) 1974-08-30 1978-07-12 Glaxo Lab Ltd Alkyl and haloalkyl androsta-1,4,15-triene and-4,15-diene-17beta-carboxylates
US4093721A (en) 1974-08-30 1978-06-06 Glaxo Laboratories Limited Pharmaceutical compositions of 6α,9α-difluoro-androst-4-ene-17β-carboxylates and derivatives thereof
YU54476A (en) * 1975-03-31 1982-05-31 Taisho Pharmaceutical Co Ltd Process for obtaining 17-ester 21-halo-pregnane
DE2538569A1 (de) 1975-08-29 1977-03-03 Siemens Ag Verfahren zur metallisierung von duroplasten
CH628355A5 (de) 1976-02-24 1982-02-26 Ciba Geigy Ag Verfahren zur herstellung neuer androstadien-17beta-carbonsaeuren und ihrer ester und salze.
US4221787A (en) 1978-03-28 1980-09-09 Interx Research Corporation Esteramide prodrugs of anti-inflammatory corticosteroids
US4187301A (en) 1978-04-05 1980-02-05 Syntex (U.S.A.) Inc. 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes
US4188385A (en) 1978-04-05 1980-02-12 Syntex (U.S.A.) Inc. Thioetianic acid derivatives
US4198403A (en) 1978-04-05 1980-04-15 Syntex (U.S.A.) Inc. 17 Beta-thiocarboxylic acid esters of 4-halo-3-oxoandrost-4-enes
US4261984A (en) 1978-04-05 1981-04-14 Syntex (U.S.A.) Inc. 17β-thiocarboxylic acid esters of 3-oxo-4-halo-16β-methylandrost-4-enes
US4263289A (en) 1978-04-05 1981-04-21 Syntex (U.S.A.) Inc. Thio etianic acid derivatives
DE2817988A1 (de) 1978-04-25 1979-11-08 Hoechst Ag Corticoid 17-alkylcarbonate und verfahren zu deren herstellung
US4310466A (en) 1979-08-31 1982-01-12 Syntex (U.S.A.) Inc. Thio etianic acid derivatives
US4267173A (en) 1979-11-05 1981-05-12 Schering Corporation Use of 6β-fluoro-7α-halogenocorticoids as topical anti-inflammatories and pharmaceutical formulations useful therefor
CY1308A (en) 1979-12-06 1985-12-06 Glaxo Group Ltd Device for dispensing medicaments
CY1291A (en) 1980-02-15 1985-10-18 Glaxo Group Ltd Androstane 17 beta carbothioates
ZA81976B (en) * 1980-02-15 1982-07-28 Glaxo Group Ltd Androstane carbothioates
US4996335A (en) 1980-07-10 1991-02-26 Nicholas S. Bodor Soft steroids having anti-inflammatory activity
US4710495A (en) 1980-07-10 1987-12-01 Otsuka Pharmaceutical Co., Ltd. Soft steroids having anti-inflammatory activity
ZA814440B (en) * 1980-07-10 1982-10-27 Otsuka Pharma Co Ltd Soft steroids having anti-inflammatory activity
ATE8790T1 (de) 1981-02-02 1984-08-15 Schering Corporation Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
CY1492A (en) 1981-07-08 1990-02-16 Draco Ab Powder inhalator
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
GR79615B (ko) 1982-10-08 1984-10-31 Glaxo Group Ltd
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4607028A (en) 1983-08-18 1986-08-19 Ciba-Geigy Corporation Novel carboxylic acid esters
LU85856A1 (fr) 1984-04-17 1986-06-11 Glaxo Group Ltd Composes de phenethanolamine
EP0179583A1 (en) 1984-10-04 1986-04-30 Merck & Co. Inc. A system for enhancing the water dissolution rate and solubility of poorly soluble drugs
US4861765A (en) 1985-06-26 1989-08-29 Jouveinal 21-alkyl-, cycloalkyl- or aryl-substituted thio steroids and pharmaceutical compositions containing them
PH26882A (en) 1985-07-30 1992-11-16 Glaxo Group Ltd Devices for administering medicaments to patients
US4994439A (en) 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
US5202316A (en) 1989-03-22 1993-04-13 Roussel Uclaf N,N,N',N'-6-(1-piperazinyl)-2,5-pyridinediamines
FR2644788B1 (fr) 1989-03-22 1995-02-03 Roussel Uclaf Nouveaux steroides 3-ceto comportant une chaine en 17 amino-substituee, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
FR2644787B1 (fr) 1989-03-22 1995-02-03 Roussel Uclaf Nouveaux steroides 21 aminosubstitues, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
JPH07116215B2 (ja) 1989-04-19 1995-12-13 エスエス製薬株式会社 新規なステロイド化合物
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
DE4025342A1 (de) 1990-08-10 1992-02-13 Hoechst Ag In 17-stellung substituierte corticoid-17-alkylcarbonate, verfahren zu deren herstellung und diese enthaltende arzneimittel
US5250293A (en) 1991-04-22 1993-10-05 Gleich Gerald J Method for the treatment of hypersensitivity diseases by administration of anionic polymers
TW247878B (ko) 1991-07-02 1995-05-21 Takeda Pharm Industry Co Ltd
US6127353A (en) 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
US5658549A (en) 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
SK279958B6 (sk) 1992-04-02 1999-06-11 Smithkline Beecham Corporation Zlúčeniny s protialergickým a protizápalovým účink
AU679511B2 (en) 1993-03-17 1997-07-03 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
DE4328819A1 (de) 1993-08-27 1995-03-02 Hoechst Ag Corticosteroid-17-alkylcarbonat-21/0/-Carbonsäure- und Kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE4333920A1 (de) 1993-10-05 1995-04-13 Hoechst Ag Corticoid-17,21-dicarbonsäureester sowie Corticosteroid-17-carbonsäureester-21-kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
US5420120A (en) 1993-12-17 1995-05-30 Alcon Laboratories, Inc. Anti-inflammatory glucocorticoid compounds for topical ophthalmic use
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
GB9419536D0 (en) 1994-09-28 1994-11-16 Glaxo Inc Medicaments
US5707984A (en) 1995-12-08 1998-01-13 G. D. Searle & Co. Steroid nitrite/nitrate ester derivatives useful as anti-inflammatory drugs
DE69609199T2 (de) 1995-12-29 2001-03-01 Glaxo Group Ltd Lacton derivate von 17.beta.-carboxy, carbothio und amide androstanverbindungen
US5981517A (en) 1996-05-09 1999-11-09 Soft Drugs, Inc. Androstene derivatives
US5919776A (en) 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
WO1999016766A1 (fr) 1997-10-01 1999-04-08 Kyowa Hakko Kogyo Co., Ltd. Derives de benzodioxole
US5972920A (en) 1998-02-12 1999-10-26 Dermalogix Partners, Inc. Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders
AU3328499A (en) 1998-03-14 1999-10-11 Byk Gulden Lomberg Chemische Fabrik Gmbh Phthalazinone pde iii/iv inhibitors
US6136294C1 (en) 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
US6261539B1 (en) 1998-12-10 2001-07-17 Akwete Adjei Medicinal aerosol formulation
GB9828721D0 (en) 1998-12-24 1999-02-17 Glaxo Group Ltd Novel apparatus and process
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US20020081266A1 (en) 1999-08-20 2002-06-27 Norton Healthcare Ltd. Spray dried powders for pulmonary or nasal administration
GB0015876D0 (en) * 2000-06-28 2000-08-23 Novartis Ag Organic compounds
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
AU7576001A (en) 2000-08-05 2002-02-18 Glaxo Group Ltd 6.alpha., 9.alpha.-difluoro-17.alpha.-`(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
WO2002051422A1 (fr) 2000-12-22 2002-07-04 Ssp Co., Ltd. Agents preventifs/remedes destines a des maladies inflammatoires des voies aeriennes
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
EP1383786B1 (en) * 2001-04-30 2008-10-15 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
US6787593B2 (en) * 2002-03-27 2004-09-07 Lear Corporation Sound-deadening composites of metallocene copolymers for use in vehicle applications
JP3691459B2 (ja) 2002-06-14 2005-09-07 久光メディカル株式会社 粉末状吸入剤組成物
DE10237739A1 (de) 2002-08-17 2004-02-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika
US7244742B2 (en) * 2002-08-17 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co Kg Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic
CA2505397A1 (en) * 2002-11-08 2004-05-21 Warner-Lambert Company Llc Phenylalkyl and pyridylalkyl piperazine derivatives
GB0526419D0 (en) 2005-12-23 2006-02-08 Cyclacel Ltd Formulation

Also Published As

Publication number Publication date
DK1383786T3 (da) 2009-01-12
US7291608B2 (en) 2007-11-06
DE60229372D1 (de) 2008-11-27
NO20034708D0 (no) 2003-10-21
PL366937A1 (en) 2005-02-07
MY137522A (en) 2009-02-27
ES2314052T3 (es) 2009-03-16
HK1062020A1 (en) 2004-10-15
HUP0400070A2 (hu) 2004-04-28
US20040171597A1 (en) 2004-09-02
EP1383786A1 (en) 2004-01-28
KR20040015218A (ko) 2004-02-18
CA2445839A1 (en) 2002-11-07
SI1383786T1 (sl) 2009-02-28
US20070297989A1 (en) 2007-12-27
AU2007201491A1 (en) 2007-04-26
WO2002088167A1 (en) 2002-11-07
JP4446661B2 (ja) 2010-04-07
AR033290A1 (es) 2003-12-10
CN1302007C (zh) 2007-02-28
NO326015B1 (no) 2008-09-01
EP2039700A2 (en) 2009-03-25
EP1383786B1 (en) 2008-10-15
MXPA03009940A (es) 2004-01-29
JP2004528354A (ja) 2004-09-16
KR100831534B1 (ko) 2008-05-22
NZ528888A (en) 2005-10-28
PT1383786E (pt) 2008-12-30
CZ20032958A3 (en) 2004-03-17
CN1527838A (zh) 2004-09-08
NO20034708L (no) 2003-12-22
BR0209271A (pt) 2004-06-15
ATE411334T1 (de) 2008-10-15
AU2002253342B2 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
IL158222A0 (en) Anti-inflammatory 17. beta-carbothioate ester derivatives of androstane with a cyclic ester group in position 17. alpha
AU7649701A (en) 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
TWI316062B (en) Anti-inflammatory compounds and uses thereof
AU2001290257A2 (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
AU2001290257A1 (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
ZA200502495B (en) Ester compound and medicinal use thereof.
AU2002356759A1 (en) 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
NZ513983A (en) Novel cyclic tetrapeptide derivatives and use thereof as drugs
AU4456601A (en) Oxa(thia)zolidine derivative and anti-inflammatory drug
ZA200300929B (en) 17.Beta.-carbothioate 17.Alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents.
AU2001261572A1 (en) 38594, a novel human transporter and uses thereof
AU5991400A (en) Manometer with direct passage
IL150904A0 (en) Cyclic hexapeptide derivatives and pharmaceutical compositions containing the same
AU2001274535A1 (en) Hydroxyformamidine derivatives and medicines containing the same
AU4876701A (en) Peptide derivatives and medicinal compositions
AU1855200A (en) A lower toxicity and anti-inflammatory and anti-exudation pharmaceutical composition
EP1284730A4 (en) MILD MEDICINES WITH ARALKYL ESTER
AU2000278943A1 (en) The illuminated remembrance monument
AU5054501A (en) Acetyltransferase and uses thereof
AU2001249697A1 (en) 32449, a novel human transporter and uses thereof
AU2001291135A1 (en) 63760, a novel human transporter and uses thereof
AU2341501A (en) A novel peptide--gammal1-pyrroline-5-hydroxy-reductase 14 and the polynucleotidecoding this novel peptide
AU2002231267A1 (en) Analogues of thiocoraline and BE-22179
AU2001253488A1 (en) 33556, a novel human transporter and uses thereof
AU5725000A (en) Pseudomycin amide and ester analogs